ISSCR News


The ISSCR and Novo Nordisk Foundation Collaborate to Host the Society’s 2028 Annual Meeting in Copenhagen
Press Release Kym Kilbourne Press Release Kym Kilbourne

The ISSCR and Novo Nordisk Foundation Collaborate to Host the Society’s 2028 Annual Meeting in Copenhagen

The International Society for Stem Cell Research (ISSCR) is proud to announce a collaboration with the Novo Nordisk Foundation to host the ISSCR Annual Meeting in Copenhagen, Denmark 27-30 June 2028.

The ISSCR Annual Meeting embodies the mission of both world-class organizations, supporting new frontiers in rigorous science to better human health. The conference is a revered global forum for stem cell science and regenerative medicine, uniting researchers, clinicians, industry leaders, and policy makers from more than 80 countries.

Read More
The ISSCR Responds to ICH’s Q1 Guideline on Stability Testing of Drug Substances and Drug Products
Press Release, Policy Kym Kilbourne Press Release, Policy Kym Kilbourne

The ISSCR Responds to ICH’s Q1 Guideline on Stability Testing of Drug Substances and Drug Products

On 28 July, the ISSCR submitted a response to the International Council for Harmonisation’s (ICH) guideline on stability testing of drug substances and drug products. The ISSCR recommends adding specific examples to clarify appropriate applications of certain studies and incorporating considerations for diverse manufacturing models, particularly decentralized manufacturing, where products are administered immediately after production. The ISSCR also advises including guidance on pluripotent stem cell bank stability testing, referencing Tissue Engineered Products (TEP), and clarifying whether ATMP combined products are covered under the term “combination of a drug product with a medical device.”

 To request the comments or learn more, contact Denise de Villa.

Read More
Alzheimer’s Disease Pathology and Potential Treatment Targets Identified in Brain Organoids
Press Release Kym Kilbourne Press Release Kym Kilbourne

Alzheimer’s Disease Pathology and Potential Treatment Targets Identified in Brain Organoids

Alzheimer's disease (AD) is the most common neurodegenerative disease in older people, affecting up to 1 in 20 individuals aged 65 and above. In addition to environmental and lifestyle factors, genetic mutations can predispose an individual to AD and some rare forms of inherited “familial” AD (fAD) are caused by known genetic mutations, with these affected individuals developing AD with high probability and at relatively young age. In most cases, AD is diagnosed at advanced stages, but pathological alterations in brain cells may arise earlier in life, particularly in fAD which is known to manifest earlier in life.

To study early-life changes in fAD brain cells, researchers including Zhen-Ge Luo and colleagues from ShanghaiTech University, China, have leveraged stem cell-derived brain organoids, to model aspects of early human brain development and function in the laboratory.

Read More
The ISSCR Releases Targeted Update to the Guidelines for Stem Cell Research and Clinical Translation
Press Release Kym Kilbourne Press Release Kym Kilbourne

The ISSCR Releases Targeted Update to the Guidelines for Stem Cell Research and Clinical Translation

The International Society for Stem Cell Research (ISSCR) released an update of its 2021 Guidelines for Stem Cell Research and Clinical Translation today. The targeted update addresses significant advances in the development and application of human stem cell-based embryo models (SCBEMs) and recommendations for research oversight outlined in a white paper from the ISSCR Embryo Models Working Group published in June.

Read More

Receive ISSCR Press Releases

Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications

Subscribe to ISSCR News.

Each month, ISSCR delivers scientific, policy, and community to your inbox .